Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer

Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment

(2017) Binlong Chen et al.   Theranostics

Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer

(2016) Yuan Sheng et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents

(2016) Huining He et al.   JOURNAL OF CONTROLLED RELEASE

Targeting HER2 for the Treatment of Breast Cancer

(2015) Mothaffar F. Rimawi et al.   Annual Review of Medicine

Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro

(2015) Dmitriy Smolensky et al.   BMC CANCER

Acid-Sensitive Peptide-Conjugated Doxorubicin Mediates the Lysosomal Pathway of Apoptosis and Reverses Drug Resistance in Breast Cancer

(2015) Yuan Sheng et al.   MOLECULAR PHARMACEUTICS

Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

(2015) Luc Rochette et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Neuronal Differentiation of Human Mesenchymal Stem Cells Using Exosomes Derived from Differentiating Neuronal Cells

(2015) Yuji S. Takeda et al.   PLoS One

Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs

(2014) Lin Zhu et al.   BIOMATERIALS

Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion

(2014) Y Hassona et al.   BRITISH JOURNAL OF CANCER

Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery

(2014) Vladimir P. Torchilin   NATURE REVIEWS DRUG DISCOVERY

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma

(2014) Zorica Milosevic et al.   Translational Research

HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

(2013) Susan Dent et al.   CANCER TREATMENT REVIEWS

Novel Peptide–Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells

(2013) Rania Soudy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems

(2012) Chie Kojima et al.   Acta Biomaterialia

Subcellular Quantification of Doxorubicin and Its Metabolite in Cultured Human Leukemia Cells Using Liquid Chromatography-Tandem Mass Spectrometry

(2012) Jinhui Xu et al.   ANALYTICAL LETTERS

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

(2012) Amy D Guertin et al.   Cancer Cell International

Multi-Target Drugs: The Trend of Drug Research and Development

(2012) Jin-Jian Lu et al.   PLoS One

Trastuzumab (Herceptin): Fig 1.

(2011) J.J. Gemmete et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect

(2011) Pascal Schlage et al.   JOURNAL OF CONTROLLED RELEASE

Tumor Targeting of MMP-2/9 Activatable Cell-Penetrating Imaging Probes Is Caused by Tumor-Independent Activation

(2011) S. M. J. van Duijnhoven et al.   JOURNAL OF NUCLEAR MEDICINE

Treatment of HER2-overexpressing breast cancer

(2010) J. Baselga   ANNALS OF ONCOLOGY

The role of HER2 in cancer therapy and targeted drug delivery

(2010) Wanyi Tai et al.   JOURNAL OF CONTROLLED RELEASE

Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise

(2009) Karen Y. Wonders et al.   INTEGRATIVE CANCER THERAPIES

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

(2009) Yutaka Tokuda et al.   Breast Cancer